Systemic Effects on Metastasis - a look beyond the tumor
Forthcoming · Sweden
Source: EU Funding & Tenders Portal
What would you do if you were diagnosed with pancreatic cancer? The chance that it would happen is not that high (life-time risk of 1/60), but neither is the chance to survive (10%). In addition, the quality of life as a patient is severely compromised by inadequate understanding of the metastatic process, and lack of targeted treatment options or biomarkers to individualize treatment, leading to
- Status
- Prospective
- Sector
- Hospital, Government
- Location
- Sweden
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Systemic Effects on Metastasis - a look beyond the tumor
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | What would you do if you were diagnosed with pancreatic cancer? The chance that it would happen is not that high (life-time risk of 1/60), but neither is the chance to survive (10%). In addition, the quality of life as a patient is severely compromised by inadequate understanding of the metastatic process, and lack of targeted treatment options or biomarkers to individualize treatment, leading to severe side-effects despite lack of treatment response in most cases. To make a difference and challenge this disease, by appreciating the systemic nature of cancer, I propose to focus on the role of the liver, the main organ of metastasis leading to subsequent death, in pancreatic cancer. I recently demonstrated the potential of using liver-derived information to predict outcomes in pancreatic cancer patients undergoing resection for localized disease (Bojmar et al., Nature Medicine, 2024). With this proposal, I suggest that the liver plays an active role in the progression of pancreatic cancer, and that this can be used to inform on treatment decisions, thereby improving the survival and quality of life in this patient group. I will investigate this concept through a translational study led by my team to evaluate treatment decisions guided by liver-based diagnostics, aiming at directing treatment locally or systemically, based on the metastatic biology of the cancer. Improving our knowledge about this stage of the disease could provide a treatment-window and open the door for tailoring chemo- and immuno-therapy, based on the systemic nature of the disease. I am uniquely positioned to lead this study, with my previous experience from the U.S., leading the first study of the human “pre-metastatic liver” in pancreatic cancer patients. Now independently established with my translational team and liver-based trials in the Swedish population, I aim to understand and tackle pancreatic cancer’s metastatic potential, thereby improving the life of afflicted patients. |
Location
Country | Sweden |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Government |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Sweden
- Pfizer Genotropin Manufacturing, Strangnas
- Pronova Biopharma Pharmaceutical Production Facility
- GEA Niro Pharmaceutical Spray Drying Facility, Copenhagen
- Kemwell Pharmaceutical Manufacturing Facility
- Pre-A market expansion to SaaS and Clinical Seq
- Active moisture control for active people
- Cobra Biologics Manufacturing Facility Expansion, Matfors
- ANOCCA (IEU TI)
